Lilly to Delist from European Stock Exchange

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has asked that it be delisted from the Euronext Paris stock exchange due to what the company calls “very low trading volume.”

Lilly also says costs and administrative requirements are part of the reason for the delisting. The Board of Directors of Euronext Paris S.A. has approved this request.  

Lilly says shareholders of its stock being traded on the European exchange will only be allowed to trade on the NYSE following the delisting date.

The pharmaceutical company says its last day of trading on Euronext Paris will be October 30, with a delisting on October 31.